Cemiplimab in the treatment of metastatic basal cell carcinoma
Authors:
- 27 May 2025
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (16) , 1999-2005
Abstract
Metastatic basal cell carcinoma (mBCC) is a rare but aggressive form of skin cancer that poses significant therapeutic challenges. Historically, systemic treatment options were limited, with hedgehog pathway inhibitors (HHIs) providing modest efficacy, but poor tolerability long term. This review explores cemiplimab, an immune checkpoint inhibitor targeting PD-1, as a novel therapeutic agent for mBCC. We examine its pharmacologic profile, clinical efficacy in clinical trials, safety and tolerability, and real-world performance. A comprehensive literature review was conducted using PubMed and clinical trial registries to assess cemiplimab's role in mBCC treatment, including its comparison to HHIs and potential in combination or neoadjuvant strategies. Cemiplimab has emerged as a transformative therapy for patients with mBCC who are intolerant to or have progressed on HHIs. Despite lower response rates compared to cutaneous squamous cell carcinoma, cemiplimab offers meaningful and durable disease control with a favorable safety profile and preservation of quality of life. Ongoing research into predictive biomarkers, neoadjuvant use, and combination regimens may further enhance its clinical utility.Keywords
This publication has 49 references indexed in Scilit:
- Health‐related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trialCancer Medicine, 2024
- Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitorsAnnals of Oncology, 2023
- Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancerCPT: Pharmacometrics & Systems Pharmacology, 2022
- Complete Remission of Basal Cell Carcinoma Following Treatment With Cemiplimab After 2 YearsJAMA Dermatology, 2021
- Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic AnalysisAdvances in Therapy, 2021
- Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignanciesJournal of Pharmacokinetics and Pharmacodynamics, 2021
- Association of Age, Sex, Race, and Geographic Region With Variation of the Ratio of Basal Cell to Cutaneous Squamous Cell Carcinomas in the United StatesJAMA Dermatology, 2020
- Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment ModalitiesJAMA Dermatology, 2017
- Immune checkpoint inhibitors in challenging populationsCancer, 2017
- Update on Metastatic Basal Cell Carcinoma: A Summary of Published Cases From 1981 Through 2011JAMA Dermatology, 2013